Collegium Pharmaceutical, Inc. (COLL)

Market Cap	1.11B
Revenue (ttm)	566.77M
Net Income (ttm)	48.16M
Shares Out	31.96M
EPS (ttm)	1.29
PE Ratio	26.98
Forward PE	11.11
Dividend	n/a
Ex-Dividend Date	n/a

Volume	193,412
Open	35.47
Previous Close	35.45
Day's Range	34.69 - 35.47
52-Week Range	20.83 - 40.95
Beta	1.05
Analysts	Buy
Price Target	38.60 (+11.02%)
Earnings Date	May 2, 2024

About COLL

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a bucc...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: May 7, 2015
• Employees: 197
• Stock Exchange: NASDAQ
• Ticker Symbol: COLL

Analyst Forecast

According to 6 analysts, the average rating for COLL stock is "Buy." The 12-month stock price forecast is $38.6, which is an increase of 11.02% from the latest price.

Price Target

$38.6

(11.02% upside)

Analyst Consensus: Buy